NICE No For AZ's Tagrisso Highlights Flaws of England's New Cancer Drugs Fund
NICE, the HTA institute for England and Wales, has said a preliminary no to AstraZeneca PLC 's lung cancer drug Tagrisso (osimertinib). According to the firm, the decision shows that certain drugs will fare badly under NICE's new system for assessing cancer drugs.
You may also be interested in...
AstraZeneca’s Tagrisso is the first product accepted for use on the National Health Service through the reformed Cancer Drugs Fund, but it took two tries to persuade HTA body NICE it should be funded at all. NICE examined Merck Sharp & Dohme’s Keytruda and it’s not impressed. The Pink Sheet takes a closer look at the new dynamics illustrated by these lung cancer treatments’ review.
Latest data from AstraZeneca's Tagrisso will help the company to convert the lung cancer drug's conditional approvals to full approvals, and boost reimbursement negotiations.
Germany’s Confidential Pricing Move Could Protect Companies From Potential Trumpian US Reference Pricing
Confidential pricing would give companies more flexibility to negotiate discounts and prevent withdrawals.